Automated determination of red cell methaemoglobin reductase activity by a continuous-flow system for screening hereditary methaemoglobinaemia. 1979

K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama

A flow diagram for the automated determination of ferricyanide reductase activity in red blood cells was prepared in the modules from AutoAnalyzer AA I (Technicon Instruments Inc). Ferricyanide reductase assay can be substituted for assay of cytochrome b5 reductase (EC 1.6.2.2), which plays a major role in reducing methaemoglobin in erythrocytes, and is defective specifically in the erythrocytes of patients with hereditary methaemoglobinaemia. The effective sampling rate of the analysis is 30/h, and less than 0.05 ml of whole blood is required. Interference of haemoglobin with absorption by potassium ferricyanide at 420 nm is effectively exculded by dialysis. This automated method was compared with the accepted diaphorase method, and it distinguished clearly the ferricyanide reductase activity of cord bloods from that of adult bloods. The activity of the blood from a patient with hereditary methaemoglobinaemia was only residual. It is suggested that the method is useful as a mass screening test for hereditary methaemoglobinaemia.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008403 Mass Screening Organized periodic procedures performed on large groups of people for the purpose of detecting disease. Screening,Mass Screenings,Screening, Mass,Screenings,Screenings, Mass
D008708 Methemoglobinemia The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed) Methemoglobinemias
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009247 NADH, NADPH Oxidoreductases A group of oxidoreductases that act on NADH or NADPH. In general, enzymes using NADH or NADPH to reduce a substrate are classified according to the reverse reaction, in which NAD+ or NADP+ is formally regarded as an acceptor. This subclass includes only those enzymes in which some other redox carrier is the acceptor. (Enzyme Nomenclature, 1992, p100) EC 1.6. Oxidoreductases, NADH, NADPH,NADPH Oxidoreductases NADH,Oxidoreductases NADH, NADPH
D004796 Clinical Enzyme Tests Analyses for a specific enzyme activity, or of the level of a specific enzyme that is used to assess health and disease risk, for early detection of disease or disease prediction, diagnosis, and change in disease status. Enzyme Tests, Clinical,Clinical Enzyme Test,Enzyme Test, Clinical,Test, Clinical Enzyme,Tests, Clinical Enzyme
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D005292 Ferricyanides Inorganic salts of the hypothetical acid, H3Fe(CN)6.
D005312 Fetal Blood Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery. Cord Blood,Umbilical Cord Blood,Blood, Cord,Blood, Fetal,Blood, Umbilical Cord,Bloods, Cord,Bloods, Fetal,Bloods, Umbilical Cord,Cord Blood, Umbilical,Cord Bloods,Cord Bloods, Umbilical,Fetal Bloods,Umbilical Cord Bloods

Related Publications

K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
March 1981, Clinical chemistry,
K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
January 2020, The National medical journal of India,
K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
March 1981, British journal of haematology,
K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
February 1963, Acta medica Scandinavica,
K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
January 1990, British journal of anaesthesia,
K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
May 1981, The Biochemical journal,
K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
May 1978, Scandinavian journal of haematology,
K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
April 1978, Medical laboratory sciences,
K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
March 1980, Analytical biochemistry,
K Tanishima, and N Fukuda, and M Takeshita, and Y Takizawa, and T Kitamura, and Y Yoneyama
April 1971, The Medical journal of Australia,
Copied contents to your clipboard!